Literature DB >> 990273

Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement.

V N Schumaker, M A Calcott, H L Spiegelberg, H J Müller-Eberhard.   

Abstract

Normal IgG and myeloma proteins of the IgG1, 2, 3,and 4 subclasses were mixed with human Clq and studied in the analytical ultracentrifuge for complex formation. Binding of IgG to Clq is apparent both from the enlargement of area and from the increase in sedimentation rate of the well-separated schlieren peak of Clq. The accurate determination of binding parameters requires that sedimentation rates be corrected for hydrodynamic interaction, and area measurements corrected for the Johnston-Ogston effect. At the highest immunoglobulin concentrations employed in these studies more than ten IgG molecules are bound to each Clq. If we assume that the number of binding sites must be an integral multiple of 6, then the data best support a 12 binding site model, although an 18 site model cannot be rule out. Myeloma IgG proteins of all subclasses bind to Clq, with affinities decreasing in the order G3 greater than G1 greater than G2 greater than G4. No binding of IgA to Clq could be detected.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 990273     DOI: 10.1021/bi00668a035

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  39 in total

Review 1.  Structural and functional anatomy of the globular domain of complement protein C1q.

Authors:  Uday Kishore; Rohit Ghai; Trevor J Greenhough; Annette K Shrive; Domenico M Bonifati; Mihaela G Gadjeva; Patrick Waters; Mihaela S Kojouharova; Trinad Chakraborty; Alok Agrawal
Journal:  Immunol Lett       Date:  2004-09       Impact factor: 3.685

2.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 3.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

Review 4.  What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.

Authors:  Dimitri A Diavatopoulos; Kathryn Margaret Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

5.  Molecular modelling of human complement subcomponent C1q and its complex with C1r2C1s2 derived from neutron-scattering curves and hydrodynamic properties.

Authors:  S J Perkins
Journal:  Biochem J       Date:  1985-05-15       Impact factor: 3.857

6.  IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

7.  Ultrastructure and composition of bovine conglutinin.

Authors:  C J Strang; H S Slayter; P J Lachmann; A E Davis
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

8.  Human immunoglobulin class and subclass specificity of Fc receptors induced by herpes simplex virus type 1.

Authors:  P J Johansson; T Hallberg; V A Oxelius; A Grubb; J Blomberg
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

9.  The binding of myelin basic protein to the Fc region of aggregated IgG and to immune complexes.

Authors:  C J Sindic; C L Cambiaso; P L Masson; E C Laterre
Journal:  Clin Exp Immunol       Date:  1980-07       Impact factor: 4.330

10.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.

Authors:  Akito Natsume; Rinpei Niwa; Mitsuo Satoh
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.